Departing from industry norms, Curie.Bio intentionally allocates a large equity stake to founders. They see this not just as fair but as a utilitarian strategy to gain a competitive advantage in sourcing the rarest and most valuable scientific ideas, which ultimately drives fund returns.

To maintain product focus and avoid the 'raising money game,' the founders of Cues established a separate trading company. They used the profits from this successful venture to self-fund their AI startup, enabling them to build patiently without being beholden to VC timelines or expectations.

Unlike venture creation firms that generate ideas internally, Curie.bio operates on a 'Freedom for Founders' principle. It believes the best ideas come from external innovators and its role is to augment them with capital-efficient support, fractional expertise, and operational help to translate those ideas into companies.

The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.

The firm’s core belief is being a fund *for* founders, trusting them to run their companies without heavy operational input. This hands-off approach gives partners the bandwidth and "permission" to go deep on their own projects, leading to spinouts like Anduril and Varda.

Peter Thiel structured Founders Fund to avoid the mediocre, consensus-driven deals that result from partnership voting. Believing all venture profits come from a few improbable moonshots, he empowered individual partners to make unilateral, high-conviction investments. This contrarian approach allows them to back outliers that a committee would reject.

Repro Novo's co-founders invested their own money for the costly process of finding and negotiating assets. This allowed them to secure a promising candidate before approaching institutional investors, demonstrating strong conviction and de-risking the initial investment for VCs.

Large, contrarian investments feel like career risk to partners in a traditional VC firm, leading to bureaucracy and diluted conviction. Founder-led firms with small, centralized decision-making teams can operate with more decisiveness, enabling them to make the bold, potentially firm-defining bets that consensus-driven partnerships would avoid.

Venture capital can create a "treadmill" of raising rounds based on specific metrics, not building a sustainable business. Avoiding VC funding allowed Donald Spann to maintain control, focus on long-term viability, and build a company he could sustain without external pressures or risks.